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8 ABSTRACT
Molecular genetic methods have successfully been employed in research on
rare, monogenic diseases. Spurred by this success, researchers have
employed the same methods for common complex traits like cardiovascular,
immunological and psychiatric disorders. In this thesis various strategic and
statistical methods were used to study the genetic component of
schizophrenia, its comorbidity and related traits.
We collected DNA samples from a large number of families affected with
schizophrenia. These samples were used for genetic studies of the etiology of
schizophrenia. We performed a genome-wide scan in a sib-pair collection
from the isolated Finnish population. The strongest evidence for linkage was
obtained on chromosome 7q22. The next strongest evidence for linkage was
seen on chromosome 1q42, in the vicinity of the locus implicated in another
genome-wide scan for schizophrenia performed in Finnish families from a
regional sub-isolate. To further position the region of interest we genotyped a
dense marker map on chromosome 1q. A total of 147 polymorphic markers on
chromosome 1 were included in this part of the study. The best evidence for
linkage was seen for a marker situated within a promising candidate gene for
schizophrenia (DISC1). Finally, we performed a third genome-wide scan using
a larger study sample than in the two previous studies. Two new regions
showing evidence for linkage were identified, one on chromosome 2 and
another on chromosome 5. The locus on chromosome 2 has not previously
been reported to be linked to schizophrenia, while the finding on chromosome
5 represents a strong replication of several other studies reporting evidence
for linkage to this region.
In another line of studies we investigated comorbid traits of schizophrenia.
First we monitored the age- and calendar-year-corrected incidence of cancer
in schizophrenic patients. This study was initiated because of previous reports
of lower cancer incidence in schizophrenic populations, a highly counter-
intuitive finding given the high rates of smoking among schizophrenia
sufferers. We were able to achieve virtually complete ascertainment of both
schizophrenia and cancer thanks to the systematic registration of both
diseases in Finland. In addition, it was possible to investigate the cancer
incidence in the first-degree relatives of the schizophrenic patients, since they
could be identified from the population register. They share on average half of
their genes with patients, but are not exposed to the disease specific
environmental factors like long hospitalization. We found a slightly increased
incidence of cancer in the schizophrenic patients, in contradiction of the
earlier evidence. We also found a moderately decreased risk of cancer in the
first-degree relatives of the schizophrenic patients. The interpretation of this
finding remains unclear, both environmental and genetic protective factors
being conceivable.
9Second, we tried to replicate a reported association between dopamine
receptor 4 (DRD4) and the human personality trait of Novelty Seeking (NS).
NS is a normally distributed trait in the population with considerable
heritability. Identification of variants in genes that affect normal personality
could give important information on the etiology of psychopathology. We did
find an association between NS and DRD4 by studying individuals with
extremely low and extremely NS high scores. Interestingly, high NS score was
associated with a different variant of the DRD4 gene in our sample than in the
original reports. This probably indicates that the studied variant in itself would
not influence NS, but rather some other variant within the same gene, or in a
gene situated very close to DRD4 on chromosome 11p.
10
 INTRODUCTION
Schizophrenia is a severe mental disorder affecting approximately one
percent of the population worldwide. It affects all aspects of cognition,
perception, affect and behavior, and is therefore one of the most disabling and
emotionally devastating illnesses known to man. The etiology of
schizophrenia is unknown, but based on family, twin and adoption studies,
genetic liability plays an important role. However, the genetic factors
underlying the disorder, as well as the environmental stressors contributing to
the onset of clinical symptoms, remain largely unknown.
Due to its relative genetic isolation, Finland is likely to offer some advantages
when searching for genes underlying complex diseases such as
schizophrenia. Since Finland first became home to a small group of settlers,
the population has expanded to its present size of slightly over five million. It
can therefore be assumed that fewer alleles of predisposing genes underlie
any disorder than in more mixed populations. This increases the potential to
localize susceptibility genes by linkage and association analysis in study
samples from this isolated population. This advantage is even more
pronounced in sub-isolates within the population with multiple bottlenecks in
the population history. We have therefore systematically collected samples
from one such inbred sub-population. To fully understand the concept of
schizophrenia it is also important to study its comorbidity. Traits that occur
more or less frequently among persons suffering from schizophrenia can shed
some light on the etiology and risk factors for either or both of the traits. Thus,
we have also investigated associated traits of schizophrenia using a unique
population cohort collected in Finland and the registers available in this
population.
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 REVIEW OF THE LITERATURE
1 Schizophrenia
1.1 Diagnosis
In 1896 Emil Kraepelin introduced the term "dementia precox" for the large
body of patients suffering from a deteriorating mental disorder with an early
onset (Kraepelin 1919). The term dementia precox emphasizes the cognitive
facet (dementia) and the early onset (precox) of the disorder. The diagnosis of
dementia precox was characterized by a deteriorating course and clinical
symptoms of hallucinations and delusions. Kraepelin distinguished the
patients suffering from dementia precox from those suffering from manic-
depressive psychosis or paranoia. The concept of schizophrenia was first
used by Eugen Bleuler in 1911 (Bleuler 1950). The term was coined to signify
a schism between thought, emotion and behavior, not split personality (a rare
disorder termed dissociative identity disorder in modern disease
classifications) as the term is often misinterpreted by the lay public. Bleuler
divided the symptoms into primary and secondary symptoms. The primary
symptoms were Associational disturbances, Affective disturbances, Autism
and Ambivalence (the four As, Table 1), and the secondary symptoms were
hallucinations and delusions. The most fundamental difference between
Kraepelin’s and Bleuler’s concepts was the deteriorating course of the illness,
fundamental in Kraepelin’s view of the disorder, but not a necessary
prerequisite according to Bleuler. The modern diagnostic systems have
clearly moved towards Kraepelin’s view, while Bleuler’s term "schizophrenia"
has become internationally accepted.
Presently, the Diagnostic and Statistical Manual of Mental Disorders, fourth
edition (DSM-IV) published by the American Psychiatric Association (1994)
and the International Classification of Diseases, 10th edition (ICD-10)
published by the World Health Organization (1994) co-exist as diagnostic
systems in clinical work and research in the industrialized world. In the
European countries, ICD-10 is the official system for clinical diagnoses, while
DSM-IV is dominant in research settings. According to DSM-IV at least two of
the following have to be present for a significant portion of time during a 1-
month period (or less if successfully treated): 1. delusions, 2. hallucinations, 3.
disorganized speech, 4. grossly disorganized or catatonic behavior, 5.
negative symptoms, i.e. affective flattening, alogia or avolition. In addition to
these characteristic symptoms, signs of the disorder have to persist for at
least six months and have a marked negative effect on social and/or
occupational functioning. It must also be confirmed that the symptoms are not
due to other disorders, like
12
Table 1. Fundamental symptoms of schizophrenia according to Bleuler (1950)
1. Association
- Lack of purpose or goal in the speech; poverty of ideas
- Stereotypy; echolalia
- Thought blocking
- Pressure of thought; clang associations
2. Affectivity
- Lack of depth to the affect; restricted affect
- Lack of consistency of affective manifestation
- Inappropriate of blunted affect
3. Attention
- Lack of selectivity of attention; impaired active attention
4. Ambivalence
- Affective ambivalence: the same concept is accompanied simultaneously by
pleasant and unpleasant feelings
- Ambivalence of will: the patient wishes and does not wish the same thing at
the same time
- Intellectual ambivalence: the patient expresses contradictory thoughts in the
same sentence
5. Autism
schizoaffective disorder and mood disorders, or to the effect of some
substance or general medical condition (Table 2). According to ICD-10, the
general criteria for schizophrenia require one of the following to be present for
most of the time during a 1-month period: 1. thought echo, insertion,
withdrawal or broadcasting, 2. some specific delusions referred to body
movements, specific thoughts or sensations, or other persistent, culturally
inappropriate and completely impossible delusions. 3. hallucinatory voices.
Alternatively, two of the following must be present most of the time for a 1-
month period: 1. any persistent hallucinations, 2. neologisms, breaks, or
interpolations in the train of thought, resulting in incoherence or irrelevant
speech, 3. catatonic behavior, 4. negative symptoms such as marked apathy,
paucity of speech, and blunting or incongruity of emotional responses (Table
3).
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Table 2. Diagnostic criteria for schizophrenia according to DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders (APA 1994)).
A. Characteristic symptoms: Two (or more) of the following, each present for
a significant portion of time during a 1-month period (or less is successfully
treated):
(1) delusions
(2) hallucinations
(3) disorganized speech (e.g. frequent derailment or incoherence)
(4) grossly disorganized or catatonic behavior
(5) negative symptoms, i.e. affective flattening, alogia, or avolition
Note: Only one Criterion A symptom is required if delusions are bizarre or
hallucinations consist of a voice keeping up a running commentary on the
person’s behavior or thoughts, or two or more voices conversing with each
other.
B. Social/occupational dysfunction: For a significant portion of time since the
onset of the disturbance, one or more major areas of functioning such as
work, interpersonal relations, or self-care are markedly below the level
achieved prior to the onset (or when the onset is in childhood or adolescence,
failure to achieve expected level of interpersonal, academic, or occupational
achievement).
C. Duration: Continuous signs of the disturbance persist for at least 6 months.
This 6-month period must include at least 1 month of symptoms (or less if
successfully treated) that meet criterion A (i.e., active-phase symptoms) and
may include periods of prodromal or residual symptoms. During these
prodromal or residual periods, the signs of the disturbance may be manifested
by only negative symptoms or two or more symptoms listed in Criterion A
present in an attenuated form (e.g., odd beliefs, unusual perceptual
experiences).
D. Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder
and Mood Disorder With Psychotic Features have been ruled out because
either (1) no Major Depressive, Manic, or Mixed Episodes have occurred
concurrently with the active-phase symptoms; or (2) of mood episodes have
occurred during active-phase symptoms, their total duration has been brief
relative to the duration of the active and residual periods.
E. Substance/general medical condition exclusion: The disturbance is not
due to the direct physiological effects of the substance (e.g., a drug of abuse,
a medication) or a general medical condition.
F. Relationship to Pervasive Developmental Disorder: If there is a history of
Autistic Disorder or another Pervasive Developmental Disorder, the additional
diagnosis of Schizophrenia is made only if prominent delusions or
hallucinations are also present for at least a month (or less if successfully
treated).
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Table 3. Diagnostic criteria for schizophrenia according to the ICD-10
Classification of Mental and Behavioural Disorders (WHO 1994).
G1. Either at least one of the syndromes, symptoms, and signs listed under
(1) below, or at least two of the symptoms and signs listed under (2) should
be present for most of the time during an episode of psychotic illness lasting
for at least 1 month (or at some time during most of the days).
(1) At least one of the following must be present:
(a) thought echo, thought insertion or withdrawal, or thought broadcasting;
(b) delusions of control, influence, or passivity, clearly referred to body or limb
movements or specific thoughts, actions, or sensation; delusional
perception;
(c) hallucinatory voices giving a running commentary on the patient’s
behaviour, or discussing the patient among themselves, or other types of
hallucinatory voices coming from some part of the body;
(d) persistent delusions of other kinds that are culturally inappropriate and
completely impossible (e.g. being able to control the weather, or being in
communication with aliens from another world)
(2) Or at least two of the following:
(a) persistent hallucinations in any modality, when occuring every day for at
least 1 month, when accompanied by delusions (which may be fleeting or
half-formed) without clear affective content, or when accompanied by
persistent over-valued ideas;
(b) neologisms, breaks, or interpolations in the train of thought, resulting i
incoherence or irrelevant speech;
(c) catatonic behaviour, such as excitement, posturing or waxy flexibility,
negativism, mutism, and stupor;
(d) "negative" symptoms, such as marked apathy, paucity of speech, and
blunting or incongruity of emotional responses (it must be clear that these
are not due to depression or neuroleptic medication).
G2. Most commonly used exclusion clauses
(1) If the patient also meets criteria for manic episode (F30.-) or depressive
episode (F32.-), the criteria listed under G1(1) and G1(2) above must have
been met before the disturbance of mood developed.
(2) The disorder is not attributable to organic brain disease (in the sense of
F00-F09), or to alcohol- or drug-related intoxication (F1x.0), dependence
(F1x.2), or withdrawal (F1x.3 and F1x.4).
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As described above, schizophrenia was demarcated as a specific diagnostic
entity at the end of the 19th century. However, it is likely that the disorder has
existed in historic times. In the literature, accounts of persons "going mad"
exist already in the classical tragedies. According to the American psychiatrist
Nancy Andreasen (Andreasen 2000) e.g. Shakespeare depicted quite
accurately the symptoms of schizophrenia in characters such as Ophelia in
Hamlet and ’Poor Tom’, son of Gloucester, in King Lear. According to other
theoreticians, however, the first accurate description of what we today call
schizophrenia occurred only in 1809, simultaneously in France and England
(Gottesman 1991). John Haslam (1764-1844), superintendent of the Bethlem
Hospital in London published the following description of unmistakable
schizophrenia:
" There is a form of insanity which occurs in young persons; and as far as
these cases have been the subject of my observation, they have been more
frequently noticed in females. Those whom I have seen, have been
distinguished by prompt capacity and lively disposition; and in general have
become the favorites of parents and tutors, by their facility in acquiring
knowledge, and by a prematurity of attainment. This disorder commences,
about or shortly after, the period of menstruation, and in many instances has
been unconnected with hereditary taint, as far as could be ascertained by
minute inquiry. The attack is almost imperceptible; some months usually
elapse before it becomes the subject of particular notice; and fond relatives
are frequently deceived by the hope that it is only an abatement of excessive
vivacity, conducting to a prudent reserve, and steadiness of character. A
degree of apparent thoughtfulness and inactivity precede, together with a
diminution of the ordinary curiosity, concerning that which is passing before
them; and they therefore neglect those objects and pursuits which formerly
proved courses of delight and instruction. The sensibility appears to be
considerably blunted: they do not bear the same affection towards their
parents and relations: they become unfeeling to kindness, and careless of
reproof. To their companions they show a cold civility, but take no interest
whatever in their concerns… Thus in the interval between puberty and
manhood, I have painfully witnessed this hopeless and degrading change,
which in a short time has transformed the most promising and vigorous
intellect to a slavering and bloated idiot." (Haslam 1809/1976)
In this description of a condition very much reminiscent of schizophrenia, we
can see two claims that have later been disproved: The higher prevalence in
females and the low heritability. Despite these shortcomings, it is clear that
the above description is referring to schizophrenia, and we can conclude that
schizophrenia has been present at least from the beginning of the 19th
century, and probably much earlier.
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1.2 Epidemiology
Epidemiologic findings in schizophrenia can guide our search for the ultimate
goal - understanding the etiology and pathophysiology of schizophrenia -
especially some consistent and quite simple findings:
The prevalence of schizophrenia has been reported to be 1-1.5% in most
studied populations (Sartorius et al. 1986; Torrey 1987). It must be noted that
since schizophrenia is normally a lifetime disorder, the lifetime prevalence and
point prevalence are essentially identical. Certain important populations in
which the prevalence deviates significantly from this figure exist. One example
is an internal isolate in Finland in which the lifetime prevalence is 2.2% and
the age-corrected lifetime risk is 3.2% (Hovatta et al. 1997). In fact, up to 50-
fold differences in the prevalence of schizophrenia have been observed (from
0.3 to 17/1000) (Torrey 1987). However, the fact remains that schizophrenia
exists at approximately the same rate in geographic regions with very different
culture, degree of industrialization, climate etc. This may suggest that these
factors cannot play a decisive role in the etiology of schizophrenia. From a
genetic perspective, this finding suggests either that A) the mutations
increasing the susceptibility to schizophrenia are very old, i.e. from the time
before the proposed emigration of the human species out of Africa some
35,000 to 89,000 years ago (Underhill et al. 2000), or B) de novo mutations in
the genes affecting susceptibility for schizophrenia have occurred at similar
rates in all populations worldwide, with the important exception of some young
internal isolates showing effects of founder mutations and genetic drift.
As was described previously, there remains some controversy over whether
accurate descriptions of schizophrenia exist before the beginning of the 19th
century, and what its possible prevalence might have been in historical times.
According to some theories, schizophrenia has probably existed as long as
the human species. This assumption is based on the necessity of
lateralization of the brain for human language capacity, and the deficient brain
lateralization seen in schizophrenic subjects (DeLisi et al. 1997). However,
this subject remains speculative and no certainty about the possible existence
of schizophrenia and its prevalence is likely to be obtained.
Schizophrenia is equally prevalent in men and women; at least there are no
consistently replicated findings to the contrary. Some studies have found an
excess of males (Hovatta et al. 1997; Kendler and Walsh 1995), while some
have found no consistent difference, especially when the diagnostic criteria
are broadened (Jablensky et al. 1992).  Men do, on average, have an earlier
onset and a more severe course of the disorder (Castle et al. 1995). The peak
age of onset for men is in the early twenties, and for women in the mid-late
twenties with a second peak in the years around menopause (Castle et al.
1995; Sham et al. 1994).
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Decreased fecundity of patients with schizophrenia has been consistently
reported (McGrath et al. 1999; Nimgaonkar 1998). Still, the prevalence of
schizophrenia seems to be relatively stable over time. Recently, a decreased
incidence of schizophrenia has been reported (Balestrieri et al. 1997; Brewin
et al. 1997; Suvisaari et al. 1999). However, no consensus regarding
decreasing incidence of schizophrenia has yet been reached and several
more or less speculative explanations for this paradox have also been
suggested. For example, the hypothesis of the "odyssean personality" was
put forward in the 1970s (Jarvik and Deckard 1977). Other theories about the
"heterozygote" or "subclinical" advantage of relatives of patients with
schizophrenia have also been suggested (Andreasen 2000).
When studying the dates of births of schizophrenic patients, a 5-8% excess of
winter-spring births has been observed for patients with schizophrenia
compared to the general population (Torrey et al. 1997). The reason for this
variation is unknown, but for example infectious agents have been suggested,
specifically influenza A epidemics (Cannon et al. 1996; Takei et al. 1996)
To be able to collect representative study samples and classify individuals
correctly with respect to disease status in a genetic study, one has to know
which phenotypes share some part of a common genetic etiology. To this end
several family studies have been performed investigating the familial
relationship between schizophrenia and other, possibly related disorders. It
has clearly been shown that the risk of several psychotic disorders is
increased among the relatives of schizophrenic probands, specifically
shizoaffective disorder, schizophreniform disorder, delusional disorder and
atypical psychosis  (e.g. Kendler et al. 1993b). Kraepelin (1919) and Bleuler
(1950) already described non-psychotic family members of schizophrenic
patients who were odd or eccentric. Using modern nosology, paranoid,
schizoid, schizotypal and avoidant personality disorders have been shown to
aggregate in families of schizophrenic probands (Kendler et al. 1993a;
Lichtermann et al. 2000). This was the basis for the use of liability classes in
our linkage studies (Studies I-III); schizophrenia was used as liability class 1
and the spectrum conditions were included as increasingly inclusive liability
classes (2-3). We also treated the individuals diagnosed with depression or
bipolar disorder as affected in a fourth liability class. This was done based on
some reports of a familial relationship between affective disorders and
schizophrenia (Maier et al. 1993), a finding not confirmed in other
epidemiologic studies (Kendler et al. 1993b). The fact that schizophrenia has
a familial relationship with the disorders mentioned above tells us that they
share some form of familial predisposition. This familial predisposition might
naturally be due to genetic factors increasing the risk to several of the
disorders. However, there must also be unique genetic factors predisposing
only to schizophrenia. Therefore, in studies I-III, we performed statistical
analyses separately for the four increasingly inclusive liability classes.
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1.3 Environmental risk factors
This thesis addresses the genetic risk factors of schizophrenia, but a brief
discussion about the environmental risk factors of schizophrenia is warranted.
As stated earlier, the etiology of schizophrenia is unknown, and so are the
environmental risk factors increasing the risk of developing the disorder.
However, some possible environmental risk factors have been identified and
are supported by observational data, these being infections, obstetric
complications, malnutrition and childhood rearing environment.
Especially second trimester exposure to influenza has been reported to be
associated with later increased risk of developing schizophrenia. In a study in
the Helsinki area, individuals whose mothers were exposed to the 1957
influenza epidemic during their second trimester of gestation had a
significantly elevated risk of developing adult schizophrenia (Mednick et al.
1988). This finding has been replicated by several studies (Barr et al. 1990;
Kunugi et al. 1995; McGrath et al. 1994; O’Callaghan et al. 1991; Takei et al.
1996; Takei et al. 1995).
There is compelling evidence of an association between pre- and perinatal
complications and schizophrenia susceptibility (Hollister et al. 1996; Jones et
al. 1998; Sacker et al. 1995). Specifically, low birth weight, short gestation,
low Apgar scores and rhesus incompatibility have been shown to be
susceptibility factors for schizophrenia.
Prenatal malnutrition has been shown to be associated with increased risk of
developing schizophrenia. Specifically, children who were exposed to the
famine in the Netherlands during 1944-45 in utero in their first trimester of
gestation had a higher risk of developing schizophrenia (Susser et al. 1996).
In a Finnish study, low maternal late-pregnancy BMI was shown to be an
independent risk factor for schizophrenia (Wahlbeck et al. 2001).
Historically, many different psychosocial factors have been argued to be
directly and causally linked to schizophrenia. This has been based on
psychoanalytic and psychodynamic theories as well as on theories regarding
the family. Very few well-designed studies have been published regarding
these factors, and many of them seem outdated to the contemporary scientist.
From a clinical point of view, these theories can be useful to understand how
the disease can affect the patient and his/her social network. It is still possible
that childhood rearing environment has an effect on the risk of developing
schizophrenia. For example lower "general understanding and management"
of their children by the mothers has been associated with a higher risk of
developing schizophrenia (Jones et al. 1994). Also, being born as the result of
an unwanted pregnancy has been associated with later schizophrenia in one
study (Myhrman et al. 1996)
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1.4 Neuropathology
The limbic system has been well studied in schizophrenia because of its
central role in the control of emotions. Many studies of post-mortem brains
from schizophrenic patients have reported decreased size of, among others,
the amygdala, hippocampus and parahippocampal gyrus (Aso et al. 2001;
Gur et al. 2000; Sigmundsson et al. 2001; Wright et al. 2000). For a review of
these findings, see Shenton et al. (2001).
The basal ganglia have also been extensively studied in schizophrenia. These
structures have a role in the control of movements, and are implicated in
schizophrenia because of the odd or stereotypical movements that many
schizophrenic patients express even without the effect of medication. Some
movement disorders involving the basal ganglia, for example Huntington’s
disorder, are also quite often associated with psychosis. The results of studies
of the basal ganglia have been less conclusive, with reports of decreased size
of the substantia nigra (Bogerts et al. 1983), increased size of the globus
pallidus (Elkashef et al. 1994), but also several negative studies (see for
example: Gur et al. 1998; Lang et al. 2001).
Total brain volume has also been found to be decreased in schizophrenic
patients. Specifically, many consistent reports of decreased lateral ventricle
volume have been published. Especially the cortical volume of brains of
schizophrenic patients has consistently been shown to be decreased. For a
review of these findings, see McCarley et al. (1999). Reports on the possible
role of the cerebellum in higher cognitive functions and some MRI findings of
increased vermis volume and cerebellar assymmetry in schizophrenic
subjects have recently been published (Levitt et al. 1999).
1.5 Endophenotypes
Schizophrenia is defined by its clinical symptoms. The diagnostic systems
developed for clinical purposes have aimed at optimizing reliability of the
diagnosis to enable clinicians to communicate. This necessarily means that
validity is somewhat sacrificed. The diagnostic systems focus on only a few of
the symptoms that the patients present with, most prominently the positive
psychotic symptoms as described above, since they are easy to
operationalize. For genetic studies and other studies aiming at identifying
pathophysiology and etiology, however, other definitions of the phenotype
might be necessary.
Kraepelin and Bleuler already stressed the importance of defining the illness
by attempting to identify a "morbid process" (Figure 1) (Andreasen 2000).
Psychotic symptoms are not specific to schizophrenia. For both Kraepelin and
Bleuler, the most characteristic feature of schizophrenic subjects was
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fragmenting of the cognitive processes, what we today would refer to as
formal thought disorder.
With this in mind, it is clear that scientists in the field of schizophrenia genetics
are interested in finding phenotypes that define some sub-group of the large
population of schizophrenic subjects, while at the same time offering a closer
relationship to the underlying pathophysiologic process. Such phenotypes
have mostly been derived from neuropsychology and neurophysiology. An
ideal endophenotypic measure should show significant and consistent
abnormality in at least a sub-group of schizophrenic subjects compared to
normal controls, and also in their first-degree relatives.
The so-called P50 evoked potential is a characteristic spike in the EEG of
both normal and schizophrenic patients occurring 50µs after a short auditory
stimulus. In normal individuals, this spike gradually vanishes after repeated
exposure to the same stimulus. In schizophrenic patients, however, this
suppression does not occur, and the same spike is seen regardless of the
number of times the stimulus is repeated. The same deficit of suppression is
seen also among the unaffected first-degree relatives of schizophrenic
patients, and again among individuals with other schizophrenia spectrum
disorders (Freedman et al. 2000). The importance of this measure has been
further emphasized by the finding of a linkage between the alpha 7-nicotinic
receptor and p50 deficit in schizophrenic patients (Freedman et al. 1997)
Between 50% and 80% of schizophrenic patients have eye-tracking deficits,
compared to 8% of the general population (Levy et al. 1993). This means that
they have an inability to accurately follow a moving visual target. This is
caused by a disinhibition of saccadic eye movements and can therefore be
thought of as yet another result of deficient inhibition. This deficit is also seen
among 25-40% of first-degree relatives of schizophrenic patients (Holzman
2000). Eye-tracking deficit can thus be viewed as a pleiotropic manifestation
of schizophrenia and might be useful as an endophenotype for genetic
studies.
Working memory, the more contemporary term for short-term memory, is
conceptualized as an active system for temporarily storing and manipulating
information needed in the execution of complex cognitive tasks, e.g. learning,
reasoning, and comprehension (Baddeley et al. 1986). As measured by the
Digit Span subtest of Weschler Memory Scale - Revised (Russell 1975),for
example, schizophrenic patients tend to show significantly impaired working
memory compared to controls (Cannon et al. 2000), and their unaffected
relatives are intermediate here, too (Krabbendam et al. 2001).
In 1996 Cloninger et al. suggested that "When a disease is caused by
interactions among multiple susceptibility dimensions, each of which may be
oligogenic, then the replication of particular genes is unlikely in samples of
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practical size. Consequently, it may be more fruitful to map genes contributing
to temperament, which has a relatively simple genetic architecture and can be
quantified easily and reliably by questionnaire." (Cloninger et al. 1996). One
such questionnaire, the TCI (Cloninger 1987) was designed and validated for
the quantitative assessment of personality disorders (Battaglia et al. 1996).
The temperament dimensions measured by the TCI have not been validated
directly as endophenotypes for schizophrenia. However, it is conceivable that
alleles contributing to the susceptibility for certain personality disorders
(schizoid, schizotypal, paranoid) belonging to the so-called schizophrenia
spectrum can have some role also in the etiology of e.g. schizophrenia.
Therefore these kind of quantitative measures of personality have been
suggested as a possible means to circumvent some of the problems
associated with mapping of susceptibility genes for major mental disorders.
1.6 Comorbidity
The positive or negative correlation of two disorders can give some clues
about the etiology of either or both of the disorders. Factors affecting the
susceptibility of both disorders can be easier to identify if a correlation
between them is observed. For example, the comorbidity between lung and
renal cell carcinoma (RCC) has led to the identification of one allele of the N-
acetyltransferase 2 (NAT2) gene as a genetic risk factor for RCC among
smokers (Semenza et al. 2001). This gene codes for a polymorphic enzyme
involved in tobacco-carcinogen metabolism and was therefore a logical
candidate gene based on the observed comorbidity. In psychiatry, the
increased morbid risk of for example schizoaffective disorder and schizoid
personality disorder among relatives of patients with schizophrenia has led to
the conceptualization of the "schizophrenia spectrum" conditions, probably
sharing some genetic risk factors (Kendler et al. 1993a). Numerous reports
have suggested that the rates of physical illness differ between patients with
schizophrenia and the general population. While most of the evidence must
be regarded as anecdotal (Baldwin 1979), some observations deserve further
study, among them a decreased incidence of lung cancer (Harris 1988;
Tsuang et al. 1983), a highly counterintuitive finding given the increased rate
and intensity of smoking among individuals with schizophrenia (Harris 1988).
In genetic terms, the hypothesis is quite attractive that some schizophrenia
vulnerability gene would at the same time decrease the risk of lung cancer
despite heavy exposure to the strongest known environmental risk factor,
tobacco smoke. A well-designed, population-based, three-center cohort study
found a decreased risk of lung cancer in patients with schizophrenia (Gulbinat
et al. 1992). A lower than expected incidence of cancers of the prostate,
cervix and corpus uteri as well as an increased incidence of female breast
cancer was observed, but not consistently so across the study centers
(Gulbinat et al. 1992). These findings might turn out to be valuable when
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mutations or DNA variants are identified in positional candidates of
schizophrenia genes, as in the example above.
2 Strategies for searching for genes behind complex disorders
2.1 Genome-wide approach
Genome-wide scanning refers to genotyping of hundreds of polymorphic
markers ordered and evenly spaced throughout the chromosomal DNA
strands. Traditionally, around 400 microsatellite markers have been used for
genome-wide scanning of both monogenic and complex disorders (Kruglyak
1997). Co-segregation of certain alleles of a marker and disease phenotype is
then evaluated in linkage analysis. This is the method of choice for identifying
novel loci without any pre-set hypothesis about the etiology of a disorder. The
disadvantage of the method is the lack of information needed to define
parameters for linkage analysis like inheritance pattern, penetrance, number
of phenocopies etc. The relatively low statistical power, especially for complex
disorders in which the locus-specific λs is not expected to be >3, probably
even less (Risch 1990a), makes it necessary to collect very large study
samples to be able to detect true linkages. The method has been highly
successful in mapping genes for monogenic disorders, but for genetically
complex human disorders very few genes have been identified based on
linkage findings (e.g. Horikawa et al. 2000).
Lately, the novel techniques for monitoring SNP markers have drawn much
attention. These techniques, like DNA-microarray technology, offer a way to
monitor several thousands of markers in large study samples, but it is not yet
clear whether they will offer a practically feasible means of tackling complex
traits. Moreover, the statistical analysis of the large amounts of data provided
by these techniques is still under debate (Weiss and Terwilliger 2000). It
seems clear that most genetic variation in human populations is due to
variation in single nucleotide polymorphisms (SNPs) (Altshuler et al. 2000). It
has also been verified that SNPs have a clearly lower mutation frequency
than microsatellite markers, making them more suitable for association
analysis where co-segregation of a marker allele and disease is monitored for
many generations (Kruglyak 1997).
2.2 Candidate gene approach
An hypothesis-driven and potentially powerful approach to the identification of
susceptibility genes for any trait is to test for association between the trait and
genes that are known or thought to be involved in the regulation of this trait.
This is certainly the case for very complex disorders, like schizophrenia,
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where detection of linkage in family materials can be difficult or even
impossible (Terwilliger 2001). Because of the lack of knowledge about the
etiology of schizophrenia the number of possible candidate genes is restricted
only by the imagination of the scientist. This places a very stringent burden of
statistical proof on positive results, because of low prior probability and issues
of multiple testing (Owen et al. 1997). Perhaps the most obvious candidate
genes are the neurotransmitters known or suspected to be involved in the
pathophysiology, if not necessarily the etiology, of schizophrenia. These have
also been extensively studied by association methods, e.g. dopamine
receptors, serotonin 5HT2A receptor, Kca3, to mention but a few. The list of
candidate genes studied in schizophrenia is very long and cannot be
discussed here. Some of them are listed in Table 4. For a detailed review of
some of these studies see O’Donovan and Owen (1999).
Table 4. Some candidate genes for schizophrenia
Gene Symbol
Dopamine receptor 1 DRD1
Dopamine receptor 2 DRD2
Dopamine receptor 3 DRD3
Dopamine receptor 4 DRD4
Dopamine receptor 5 DRD5
Dopamine transporter SLC6A3
5-hydroxytryptamine type 2a receptor 5-HT2a
Tyrosine hydroxylase TH
Prohibilinogen deaminase PBGD
Calcium activated potassium channel hKCa3/KCCN3
Disrupted in Schizophrenia 1 and 2 DISC1 and 2
Reelin RELN
Neuronal nicotinic cholinergic receptor alpha2 CHRNA2
Homologous to Drosophila Notch - 4 NOTCH4
Brain-derived neurotrophic factor BDNF
Neurotrophin-3 NT-3
Serotonin transporter promoter region 5-HTTLPR
Myo-inositol monophosphatase 2 IMPA2
Tumor necrosis factor alpha TNFα
Catechol-O-methyltransferase COMT
Spinocerebellar ataxia 1 SCA1
2.3 Statistical methods
The ultimate goal of any genetic study of complex disorders is to find a
functional variant that has an effect on disease susceptibility. Any base within
the genome can theoretically be a causative variant, but with present
techniques it is not practicable to directly study every base in the genome.
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Therefore alternative approaches have to be employed to localize the regions
most likely to contain susceptibility genes. The most widely used methods are
linkage analysis, association analysis, allele-sharing methods and animal
models (Lander and Schork 1994).
2.3.1 Linkage and association analysis
Traditional linkage analysis is often referred to as "parametric" analysis since
one has to specify the parameters a priori. These are the allele frequency,
penetrance and phenocopy rate. One monitors the co-segregation of marker
alleles with the studied phenotype. The statistic most commonly used is the
lod score (Z), which is given by the formula:
in which L is the likelihood function and Θ is the recombination fraction
(Morton 1955). The most likely distance between two loci (e.g. a marker and a
gene) is the recombination fraction at which the lod score peaks. However,
since any error in the specified parameters, i.e. the disease model, will
influence the estimation of the recombination fraction (Goring and Terwilliger
2000a), this property of the lod score is of no use in the localization of
susceptibility genes for complex disorders (Figure 2). Classically, an odds
ratio of more than 1000:1 in favor of linkage (equal to a lod score of 3) has
been interpreted as statistically significant evidence for linkage in monogenic
disorders (Conneally et al. 1985; Morton 1955).
Figure 2. Diagram showing a theoretical model for the relationship between
marker loci, disease genes and phenotype. In linkage and association
analysis we study relationship A, whereas the true relationship between
marker loci and phenotype is B + C. Relationship C is complicated by
environment and other genes as well as incomplete penetrance and
phenocopies.
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For complex disorders, somewhat modified criteria have to be used. Lander
and Kruglyak have suggested three different categories for interpreting
significance of genome-wide scans, namely suggestive, significant and highly
significant linkage. These would be expected to occur one, 0.05 and 0.0001
times in a genome-wide scan respectively, and would correspond to lod
scores of 2.2, 3.6 and 5.4 in a sib-pair study (Lander and Kruglyak 1995).
These guidelines have been widely accepted by the field, but are arbitrary in
nature, and have also been criticized (Elston 1997; Morton 1998). Only
confirmation of the finding in a separate study sample will convince
researchers in the field that the linkage is not a false positive finding.
Allele-sharing methods, such as the affected sib-pair method, are alternations
of traditional linkage analysis and are often referred to as "model free",
because no parameters have to be specified. However, it has been shown
that for example the mean test, which can be considered the most prominent
of the affected sib-pair tests, is equivalent to lod score analysis for an
assumed recessive mode of inheritance, irrespective of the true mode of the
disease (Knapp et al. 1994). Therefore, traditional linkage analysis and allele-
sharing methods are actually conceptually very similar.
Association analysis on the other hand is equal to linkage analysis in a very
large pedigree, namely the whole population from which the study sample is
drawn (Terwilliger and Goring 2000). Because of the large number of meioses
in such a pedigree, the region in which a signal can be detected is relatively
small, but within that region the statistical power is greater than for traditional
linkage analysis. One could therefore interpret association analysis as yet
another variant of traditional linkage analysis. Since animal crossing studies in
gene identification ultimately use association (or linkage) analyses for
identification of disease alleles, all four methods described by Lander and
Schork (1994) can actually be thought of as variations of one method.
Linkage analysis can be performed by comparing co-segregation of one
marker with disease status (two-point linkage analysis), or information can be
extracted from several markers at a time (multipoint linkage analysis) as
implemented in several statistical software programs, e.g. Genehunter
(Kruglyak et al. 1996), and SimWalk2 (Sobel and Lange 1996). Using
complete information, two-point and multipoint analysis are identical, but in
the case of missing data for one marker, multipoint methods can increase the
information obtainable for loci close to that marker. However, they are
sensitive to inconsistencies in recombination fractions between markers,
commonly occurring genotyping errors and persisting errors in the marker
map (Goring and Terwilliger 2000b).
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2.3.2 Quantitative measures
Psychiatry has been dominated by different diagnostic classifications like the
DSM (APA 1994) and the ICD (WHO 1994) diagnostic systems. In such
diagnostic systems, a person is classified as affected if he/she fulfills certain
diagnostic criteria. They are therefore by nature dichotomous. Systems like
these are needed to construct treatment guidelines. However, DSM-IV states
that "there is no assumption that each category of mental disorder is a
completely discrete entity with absolute boundaries dividing it from other
mental disorders or from no mental disorder" (p. xxii).  Indeed, in natural
populations, variation in most characters takes the form of a continuous
phenotypic range rather than discrete phenotypes. Probably most psychiatric
disorders are also extremes either of normal behavior or of some underlying
susceptibility to the disorder. As described above (1.5 Endophenotypes)
several quantitative measures that reflect schizophrenia liability have been
identified. These include neuropsychologic traits like working memory,
neurophysiologic traits like eye-tracking, and neuroradiologic traits like size
and activation of different brain-regions, to mention a few. These are all
measured quantitatively and can be assessed in both patients and their
unaffected relatives.
There are several statistical computer programs available to perform genetic
linkage analysis utilizing this kind of quantitative phenotypic data. Probably
the most prominent is the SOLAR package (Almasy and Blangero 1998),
which uses a variance components approach to calculate IBD matrices for
pedigrees of any size, and then perform two-point or multipoint analysis for
the marker data. The idea is that if the studied trait, or some underlying risk
factor, is measurable on a quantitative scale it should be used as such.
Dichotomizing the trait into affected and non-affected classes causes a lot of
information to be lost and diminishes the power to detect linkage (Duggirala et
al. 1997).
2.3.3 The issue of power in a linkage study
To be able to plan the research, to use the appropriate amount of resources,
and to interpret the results, it is useful to have some grasp of the statistical
power of a certain study sample in linkage analysis.  For a monogenic
disorder the estimation of statistical power of a study sample of a certain size
is relatively trivial. Several software programs are available to calculate the
probability of finding linkage above a certain threshold in a given study
sample, e.g. Simlink (Boehnke 1986). This kind of statistical power analysis is
possible also for oligo- and polygenic disorders by specifying several
parameters a priori, these being the number of genes underlying the disorder,
the disease gene frequency, and the heritability and penetrance of the
disorder, in addition to information about the study sample. In a disorder like
schizophrenia all these parameters are unlikely to be correctly estimated, with
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the possible exception of heritability (e.g. (Cannon et al. 1998)). The number
of genes underlying schizophrenia can be indirectly estimated from the
steepness of decrease in incidence with decreasing biological relatedness
with a proband. However, this is confounded by familial and unique
environmental risk factors and also by epistatic interactions between
susceptibility loci. The product of disease gene frequency and penetrance is
correlated with the lifetime prevalence, but the magnitude of the two factors
cannot be reliably determined in schizophrenia.
Despite this, a priori power calculations have been made for many
schizophrenia studies, often showing that the studies would have had the
power to detect linkage. The repeated failure to find genes for schizophrenia
provides substantial evidence that the assumed architectures of the disease
postulated by many researchers in the field are grossly oversimplified.  For
this reason, since all we know is that the etiology must be more complicated
than has been expected previously, power calculations were considered a
gratuitous exercise in our studies. For a detailed review of the problems of
power estimation in linkage studies for complex disorders, see for example
(Terwilliger and Goring 2000).
Based on the experience of previous genome-wide scans for schizophrenia, it
was clear already from the start of this project that obtaining sufficient
statistical power was going to be a major problem. We undertook several
strategies to circumvent some of these problems; 1) We collected as large a
study sample as was possible using the resources available. 2) The familiar
enrichment of the disorder was maximized, especially in the internal isolate,
by collecting families with as many affected individuals as possible. 3) We
tried to maximize genetic homogeneity of the study sample by collecting large
numbers of families from the more genetically isolated regions in the
northeastern parts of Finland. Only the outcome of the present studies aiming
at identifying disease-causing variants in the regions identified in the linkage
studies will provide a definitive answer as to whether these strategies were
successful.
2.4 Isolated populations
Genetically isolated populations offer many advantages for genome-wide
mapping studies: the founder effect and high degree of inbreeding in small
population isolates result in an increased incidence of some recessive
disorders, causing some otherwise rare disorders to be found at relatively
high rates. Typically, only in these special isolates can cases of rare diseases
be found in sufficient number for the phenotype to be defined and for genetic
mapping projects to be carried out.
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Due to the founder effect and isolation, the monogenic diseases are less likely
to show both locus and allelic heterogeneity. In fine mapping of positioned
loci, strategies using LD and haplotype-sharing between affected individuals
can thus be applied to efficiently restrict the critical DNA region (Peltonen et
al. 1999; Peltonen 2000).
Based on the findings in monogenic diseases, an appropriate hypothesis
considering the genetic background of multifactorial diseases would be that in
isolated populations fewer disease-predisposing alleles and, potentially, fewer
influencing genes behind a given trait will be encountered than in populations
of more heterogeneous origin (Collins 1995; Lander and Botstein 1986;
Lander and Schork 1994; Peltonen et al. 2000). Several genetic-mapping
studies in multifactorial diseases have been carried out in study samples from
isolated populations, including bipolar disease in Old Order Amish (Ginns et
al. 1996) and Costa Rican populations (Freimer et al. 1996), for a review see
(Peltonen et al. 2000). Finnish subpopulations have also been used in genetic
studies of complex diseases like multiple sclerosis (Kuokkanen et al. 1997),
diabetes (Mahtani et al. 1996), schizophrenia (Hovatta et al. 1999) and
familial combined hyperlipidemia (Pajukanta et al. 1998). All these studies
have been based on the collection of large pedigrees with multiple affected
individuals, facilitating the use of traditional linkage analyses, and have in
most cases resulted in the initial positioning of several susceptibility loci. So
far, no specific susceptibility gene has been identified on the basis of these
studies, and therefore the genetic background of multifactorial diseases in
isolates like Finland cannot yet be characterized.
Importantly, no genome scan for predisposing loci in complex diseases
among genetic isolates has provided evidence for LD, even when relatively
high-density maps with marker intervals of 1-2 cM have been used. However,
candidate gene-based studies have revealed association between intragenic
markers and complex traits, for example in two Finnish studies on
hypertension and multiple sclerosis (Kainulainen et al. 1999; Tienari et al.
1994b). In a genome scan for schizophrenia loci in families collected from one
sub-isolate of Finland, no statistically significant association was detected
using a marker map with a 1 to 2-cM marker interval. This isolate is only 15-
17 generations old, but has shown an expansion rate of 170% during the past
100 years, and this has probably resulted in the rapid decay of LD in disease
alleles (Hovatta et al. 1997). Based on this limited experience, it seems that
genetic intervals revealing LD in common disease alleles in Finland are much
more restricted than in the case of monogenic diseases. This is probably due
to anticipated locus heterogeneity, and the fact that several predisposing
mutations have been introduced even into genetic isolates. However, it should
be emphasized that alleles from different regions of Finland reveal different
interval of LD. Mounting evidence from the Finnish population suggests that
LD does extend significantly further in certain sub-populations than in the
general population of Finland (Mohlke et al. 2001; Varilo et al. 2000; Varilo
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personal communication). This further underlines the importance of careful
selection of study population and genealogical tracing of ancestors.
Recent theoretical studies of populations with different demographic histories
have actually suggested that although rapidly expanding populations (such as
the Finns) are ideally suited for mapping of rare monogenic disease genes,
old and stable populations (such as the Lapps) may be better for mapping
genes for complex diseases that are probably caused by older, common
mutations (Laan and Paabo 1997; Slatkin 1994; Terwilliger et al. 1998). In
isolated populations of small constant size, the drift probably generates new
disequilibrium more quickly than recombinations and mutations result in its
decay. The power of isolates with disparate genealogical history in the
mapping and positional cloning of common disease genes remains to be
demonstrated. Shared environmental and cultural homogeneity in many
isolates might ultimately be even more beneficial than actual or assumed
genetic homogeneity.
3 Genetics of schizophrenia
3.1 General aspects
Scientists believed for most of the past century that genes play a role in the
etiology of schizophrenia (Tsuang et al. 1999). The first systematic family
study dates back to 1916 and was performed by Rüdin and Kraepelin in
Munich (reviewed in Gottesman 1991). Technical advances in the field of
genetics, especially the use of polymorphic repeat sequences as genetic
markers (Botstein et al. 1980),made it possible to begin studies of the genetic
etiology of schizophrenia in the 1980s, mostly using single families densely
loaded with schizophrenia. The first promising report of a genetic linkage to
schizophrenia was published in 1988 (Sherrington et al. 1988), but this finding
has not been replicated (McGuffin et al. 1990).
3.2 Heritability of schizophrenia
The majority of studies show that schizophrenia runs in families. The
population lifetime prevalence of schizophrenia is about 1%. The risk for
relatives of schizophrenic subjects to develop the disorder is higher the closer
the genetic relationship is, i.e. the more genes the relative shares with the
schizophrenic subject. The prevalence in relatives is shown in detail in Table
5 (Tsuang 2000).
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Table 5. Morbid Risk of Schizophrenia for Relatives of Schizophrenic
patients (Tsuang 2000).
Relationship % Shared genes Risk (%)
General population N.A. 1
Spouses of patients N.A. 2
Third-degree relatives 12.5
     First cousins 2
Second degree relatives 25
     Uncles/aunts 2
     Nieces/nephews 4
     Grandchildren 5
     Half-Siblings 6
First-degree relatives 50
     Parents 6
     Siblings 9
     Children 13
     Siblings with 1 schizophrenic parent 17
     Dizygotic twin 17
Monozygotic twin 100 48
Children with 2 schizophrenic parents 100 46
However, the fact that the trait runs in families does not tell us whether this is
due to genetic or to familial-environmental causes. To elucidate this matter a
large number of well-designed family and twin studies have been performed.
Some evidence from adoption studies also exists.
Twin studies are in many respects the best way to disentangle genetic effects
from environmental ones. Higher concordance between monozygotic twins
than between dizygotic twins clearly suggests a role of genes in the etiology
of the disorder. Twin studies have consistently showed a high heritability of
schizophrenia in several populations (Cannon et al. 1998; Cardno et al. 1999;
Kendler and Diehl 1993). Specifically, the Finnish study by Cannon et al.
(1998) estimated the heritability of schizophrenia at 83%, while the remaining
17% was attributable to unique environmental factors. Common
environmental factors had no influence on liability. Similar findings have been
observed in the other studies.
The Copenhagen High Risk Project (Cannon and Mednick 1993) found a
prevalence of schizophrenia of 16.2% in offspring of schizophrenic mothers
compared to 1.9% in the control group (Parnas et al. 1993). In the New York
High Risk Study (Erlenmeyer-Kimling et al. 1997) schizophrenia was
observed only among offspring of parents with schizophrenia, not in the
control group. The same result was reported by the Israeli High Risk Study
(Ingraham et al. 1995)
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Two Danish adoption studies of schizophrenia (Kendler et al. 1994; Kety et al.
1994) found an increased risk of schizophrenia among biological relatives of
probands with the same disorder, but no increase in adoptive relatives
compared to the general population. The Finnish Adoptive Study of
Schizophrenia (Tienari et al. 1994a) reported similar findings.
3.3 Previous findings of linkage in schizophrenia
The following is an overview of the linkage findings reported in schizophrenia.
Linkage has been reported to most human chromosomes by some group, and
replications have been rare, with some important exceptions. Table 6 shows
the genome-wide scans for schizophrenia published to date.
Chromosome1: Brzustowicz et al. (2000) reported strong linkage (Zmax =
6.50) to chromosome 1q21-22 in a genomewide scan of 22 Canadian
pedigrees. The families included in the study had been selected so that they
all showed a dominant mode of inheritance. Still, quite paradoxically, the
recessive model and narrow disease definition showed the strongest evidence
for linkage. Gurling et al. (2001) reported evidence for linkage (Zmax = 3.2) to
marker D1S196, situated close to the linkage peak identified in the study by
Brzustowicz et al. Weak support for linkage to 1q22-23 was already reported
in an earlier study (Shaw et al. 1998). The hKCa3/KCNN3 gene, a potassium-
channel gene earlier reported to be associated with schizophrenia (Dror et al.
1999) is located in 1q21.
Somewhat further telomeric of the findings mentioned above, in the region
1q32-42, there are several independent findings of linkage to schizophrenia.
Hovatta et al. (1999) reported a three-stage genomewide scan in 69 families
from a Finnish population isolate. They observed a maximum LOD score of
3.82 at marker D1S2891, under a dominant model and a narrow disease
definition. A putative 6 cM haplotype, which might narrow the chromosomal
region implicated, was observed in some core families. In their study of
multiplex kindreds from Daghestan, Bulayeva et al. (2000 and personal
communication) found a lod score of 1.8 for marker D1S2141 in the same
region. In addition, one interesting linkage finding in bipolar disorder maps to
the same marker (Detera-Wadleigh et al. 1999).
Chromosome 2: In their study of 17 extended pedigrees from Palau,
Micronesia, Coon et al. found the strongest evidence for linkage on
chromosome 2p for marker D2S441 (Zmax=2.17) (Coon et al. 1998). This
finding from an isolated population was later replicated by Shaw et al. in a
more mixed US population (Shaw et al. 2001) (D2S139, lod=2.25).
Chromosome 4: Hovatta et al. (1999) also observed a maximum LOD score of
2.74 at marker D4S1586 on chromosome 4q31, under a dominant model and
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a narrow diagnostic model. On the other arm of this chromosome, Williams et
al. reported the strongest evidence for linkage in their genome-wide scan
(MLS=1.73, D4S3009) (Williams et al. 1999).
     
Chromosome 5: Silverman et al. (1996) reported a maximum LOD score of
4.37 at locus D5S111 on chromosome 5p14, under dominant inheritance and
a broad disease definition, in one large Puerto Rican pedigree.
Based on a genome scan of 265 Irish pedigrees, Straub et al. (1997)
reported a maximum heterogeneity LOD score of 3.35 at marker D5S804 on
chromosome 5q31, under a recessive genetic model and a narrow diagnostic
model. Schwab et al. (1997) reported additional support for this region
(marker D5S399). In a recent genome-wide scan of British and Icelandic
pedigrees Gurling et al. (2001), reported a lod score of 3.6 in this same
region.
     
Chromosome 6: Straub et al. (1995), tested for linkage to 6p22-24 in 265 Irish
families. They reported a maximum LOD score of 3.51 at marker D6S296,
under an additive genetic model and a broad definition of schizophrenia.
Additional support for linkage to this region was reported by Schwab et al.
(1995; 2000), by Moises et al. (1995), and by Antonarakis et al. (1995). Cao et
al. (1997) reported weak evidence for linkage to 6q21-22 in two independent
samples: p = 0.00018 at locus D6S474, and p = 0.00095 at D6S424. Martinez
et al. reported a nonparametric lod score of 3.82 in 141 independent sib-pairs
(Martinez et al. 1999).
On the other arm of chromosome 6, Lindholm et al. recently reported a
lod score of 3.45 (D6S264) from a very large Swedish pedigree (Lindholm et
al. 2001)
Chromosome 8: Blouin et al. (1998) reported a nonparametric lod score of
3.64 at D8S1771 on chromosome 8p21. When a broad disease definition was
used in this sample, support for linkage increased, yielding a nonparametric
lod score of 6.17 (Pulver et al. 2000). In addition, Kendler et al. (1996)
reported a lod score of 2.34, using a dominant genetic model and a broad
disease definition, in 265 Irish pedigrees. Further support for linkage to 8p21
was reported by Brzustowicz et al. (1999), with a maximum LOD score of 3.49
at marker D8S136, under a dominant model and narrow disease phenotype,
in 21 Canadian families. Also, in their recently published genome-wide scan,
Gurling et al. reported a lod score of 3.6 in this region (Gurling et al. 2001).
Chromosome 9: Hovatta et al. (1999) also observed a maximum LOD score of
1.95 at marker D9S922 on chromosome 9q21, under a dominant model in the
families from a regional subisolate of Finland.
    
Chromosome 10: Faraone et al. (1998) reported nonparametric lod scores of
3.4 and 3.2 at markers D10S1423 and D10S582, respectively, both on
chromosome 10p12.  Schwab et al. (1998) found support for this region with a
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nonparametric lod score of 3.2 at marker D10S1714. Straub et al. (1998)
observed a multipoint heterogeneity lod score of 1.91 with markers D10S1426
and D10S674. Recently, Shaw et al. reported the strongest evidence for
linkage (lod=3.55) in their genome-wide scan in the same region (D10S189).
Chromosome 13: Blouin et al. (1998) reported a nonparametric lod score of
4.18 near D13S174 on 13q32. Further support for this finding was published
by Brzustowicz et al. (1999), with a maximum heterogeneity lod score of 4.42
at D13S793.
Chromosome 15: Stober et al. (2000) reported linkage (NPL = 3.57) to 15q15
(D15S1012) in a study of periodic catatonia, a severe sub-phenotype of
schizophrenia. This region is located close to the 7 nicotinic acetylcholine
receptor gene (CHRNA7), a potential candidate gene, also implied in a study
of the p50 sensory gating deficit (Freedman et al. 1997).
Chromosome 22: Pulver et al. (1994) observed a maximum lod score of 2.82
at marker locus IL2RB on chromosome 22q13. There have been other reports
of weak linkage to the same region (Coon et al. 1994; Polymeropoulos et al.
1994; Stober et al. 2000). This region is close to the velocardiofacial
syndrome (VCFS) deletion, which is reportedly associated with psychotic
features (Murphy et al. 1999).
Chromosome X: The Finnish isolate study (Hovatta et al. 1999) reported a
maximum lod score of 2.01 at the MAOB locus on chromosome Xp11. Some
other studies have also found positive lod scores in the close vicinity of MAOB
(Dann et al. 1997; DeLisi et al. 1994).
As is obvious from the overview above, some regions have been identified by
several independent studies. Due to the large number of studies published to
date and the possibly large number of negative replications not published, the
significance of these replications is still hard to estimate. It is obvious that the
linkage findings in schizophrenia are dispersed throughout the genome. There
are several possible explanations for this. First, it could be a reflection of the
truly genetically heterogenous etiology of the disorder. Most studies have
been performed in different populations with different genetic background.
However, methodological differences could also cause inconsistency in the
results from different studies. For example, the definition of the phenotype has
traditionally varied somewhat, even though in the more recent studies DSM-IV
has generally been used as the gold standard. Whether or not diagnostic
interviews have been performed can also affect the result of any given study.
Since in most studies certain chromosomal regions are selected for further
study based on the statistical analyses of the initial stages, even small
differences in the statistical tools used can have an impact on the
interpretation of the results. Such differences include for example the use of
two-point versus multipoint or parametric versus non-parametric statistics.
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Taken together, we cannot with certainty conclude whether these results
reflect the true nature of the disorder studied or the shortcomings of the
methods used to study it, but probably both factors play a role.
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 AIMS OF THE PRESENT STUDY
1. To use the genome-wide approach to search for genetic loci predisposing
to schizophrenia in epidemiologic study samples collected in Finland.
2. To finemap one of the identified genomic regions and to investigate
whether similar evidence for linkage or any evidence for association can
be observed in disease alleles from different sub-populations within
Finland.
3. To address comorbid traits of schizophrenia by testing association of a
basic temperament measure and the DRD4 gene and by monitoring
cancer risk in schizophrenic patients.
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MATERIALS AND METHODS
 
Please refer to the original articles (I-V) and references for a more detailed
description of the studies.
1 Study samples
1.1 Schizophrenia study sample
1.1.1 Identification of eligible individuals
The schizophrenia study sample was collected by utilizing three nationwide
registers. All persons born between 1940 and 1969 and receiving free
medication or a disability pension because of schizophrenia from the Social
Insurance Institution of Finland were identified (N=17,930). Later, persons
from the same cohort who had been hospitalized for schizophrenia at least
once according to the Hospital Discharge Register were also identified,
yielding a total of 29,124 individuals with a diagnosis of schizophrenia in any
of the three registers. These data were linked to the National Population
Register in order to identify all first-degree relatives of the patients and
construct pedigrees (Figure 3).
1.1.2 Ascertainment of diagnosis
All available inpatient and outpatient records were collected for probands and
relatives with any psychiatric diagnosis in any of the three registers. Two
independent psychiatrists or psychiatric residents made DSM-IV best-
estimate lifetime diagnosis. In case of disagreement, a third reviewer made a
diagnosis to achieve a consensus diagnosis. One of the reviewers also filled
out the OPCRIT checklist (McGuffin et al. 1991) for use in the future. The
register diagnosis of schizophrenia has repeatedly been shown to have high
reliability in Finland (Cannon et al. 1998; Isohanni et al. 1997; Mäkikyrö et al.
1998; Pakaslahti 1987). Diagnostic agreement between the different
reviewers was good or excellent (see the attached articles for details on the
different study samples).
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Figure 3. Flow-chart describing the identification of subjects for the
schizophrenia study from the registers.
1.1.3 Internal isolate
Based on the settlement history of Finland, we treated the national study
sample as two separate samples during the collection stage and also partly in
the analytic stage, as described below. The population of the internal isolate
in the north-eastern part of Finland was treated as a separate population
based on genealogic data. The population of this area consisted of two Saami
villages in the wintertime until the immigration of Finnish settlers at the end of
the 17th century. The Finns came mainly from Ostrobotnia and South Kainuu,
both groups having originated from Savo (Figure 5). Mr. Matti Hiltunen, the
first Finnish pioneer to the district moved there in 1676. In 1685, the Finnish
Hospital
discharge register:
Hospitalisation
for schizophrenia
Social insurance
institution:
Disability
pension
Social insurance
institution:
Free medication
29,124 persons
with schizophrenia
born between
1940 and 1969
National
population register
Construction of
pedigrees
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population of the district consisted of 194 individuals in 34 families, and the
Saami population in the district was approximately twice as large. The great
famine in 1695-1697 killed about half of the Finns in the region and the
majority of the Saami. In 1718, parish registers were established in the
district, where there were currently 165 households and 615 individuals. Since
then the population has expanded rapidly to its present size of over 18,000
(Figure 4). The population of this district remained almost completely isolated
until World War II, and even since then, immigration to the district has been
insignificant. These circumstances and history mean that the population of the
district resembles an immense pedigree with several inbreeding loops. It is
possible to obtain genealogic information on all living persons in the district
back to 1718 using the registers administered by the Evangelic Lutheran
Church of Finland and later the Finnish population register.
Figure 4. Graph showing the growth of the Finnish population and the 
population in the internal isolate
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1.2 Oulu 66 Cohort
Cohort-66 is a longitudinal one-year-birth-cohort study from an unselected
population. The original purpose of the study was to describe and analyse the
risk factors for perinatal deaths and low birth weight. The original names of
the study were "North Finland premature-birth study" and "Development study
of children in North-Finland". The project was later named "The mother-child
cohort study of morbidity and mortality during childhood with the special
purpose of preventing mental and physical handicap" and "Cohort-66 study".
Cases belonging to the survey were determined by the calculated term: the
series comprised all mothers in Finland’s two northernmost provinces of Oulu
and Lapland with calculated term falling between January 1 - December 31,
1966. A small percentage of the births in fact occurred towards the end of
1965 and early in 1967. The calculated term, as was customary at that time,
was counted from the first day of the last menstrual period. Where this date
Internal
isolate
Late
Settlement
Early Settlement
Figure 5. The settlement of the internal
isolate utilized in our studies. Settling
of the internal isolate started in the
1680s, and originated from Savo
(shaded area).
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Figure 6. Overview of the data collection process of the Oulu66 Cohort study in the
previous stages of the study. The TCI data for Study V was collected at age 31.
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was unknown the expected term was estimated from the date of
commencement of foetal movements and progress of the pregnancy. The
study covered all live born and stillborn infants with a birth weight of 600
grams or more (Rantakallio 1969, 1988).
This sample is ideally suited to our purposes since the original cohort
represents, without selection, all individuals born during one year in a
geographically defined and culturally relatively homogeneous area. A large
number of variables have been collected during regular follow-up
examinations of participants throughout various stages of life from the
prenatal period up to age 31 (Figure 6). In 1997, 8,411 of the original cohort
members (N=11,637 alive in 1997) were living in the two northernmost
provinces of Finland or in the capital area and were therefore considered
eligible for the 31-year follow-up study in 1997-8. Among those who followed
the invitation to a clinical examination, 5,041 subjects (83%) completed a
personality questionnaire and gave written informed consent. This represents
43% of the cohort members alive at age 31, and 60% of the eligible. After
exclusion of individuals with incomplete questionnaire and/or other
background information, 4,691 individuals remained for our analyses.
1.3 Cancer comorbidity sample
The Finnish Cancer Registry was founded in 1952. It collects data on all
cancer cases in the population of Finland and publishes statistics on cancer
incidence. The Registry is countrywide and population-based (population 5.1
mill.). Informants who submit data on cancer patients to the cancer registry
include all hospitals, physicians, pathological, cytological and hematological
laboratories, and dentists. Data are also obtained via death certificates. The
annual statistics on the occurrence of cancer give numbers of cases and
incidence rates by gender, primary site, age and health care district. Tabular
material by other or more detailed parameters can also be produced. This
service is usually charge-free. Data identifying individual cancer patients can
only be obtained for research purposes; permission granted by STAKES
(National Research and Development Centre for Welfare and Health) is
always needed.
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All medical care in Finland is provided by a national health care system to
which everybody has almost cost-free access. This results in extraordinarily
complete, unbiased ascertainment of cancer cases by the registers. The
Finnish cancer registry has since 1961 continuously received obligatory
reports on all newly diagnosed cases of cancer from hospitals, practicing
physicians and hematological and pathological laboratories all over Finland,
with about 90% of diagnoses based upon histological confirmation (Research
1997).  Death certificates mentioning cancer are automatically forwarded from
Statistics Finland to the Cancer Registry for review, although less than 2% of
all cancer cases come to their attention in this way alone (Figure 7).
Ascertainment of cancer cases has been shown to be virtually complete
(Teppo et al. 1996).
In Finland medical or forensic autopsy is performed in 32% of all deaths, and
in those occurring before the age of 65 years the proportion is 64% (Statistics
Finland 1999). Forensic autopsy is also performed on all cases of violent
death, including suicide. Since about 40% of the excess mortality in
schizophrenia is accounted for by unnatural causes (Brown 1997) the autopsy
rate is, if anything, higher among schizophrenic patients than in the control
population, but the difference is expected to be small since the rate is also
exceptionally high in the control group.
Figure 7. Schematic overview of the registration of cancer cases in the
Finnish Cancer Registry.
National Health Care System (cost-free access)
Hospitals and GPs
Hematological and
pathological laboratories
Autopsy
-medical: 32% (>65 yrs: 64%)
-forensic (violent death: 100%)
Finnish Cancer Registry
>90%
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2 Laboratory methods
2.1 Sample collection and DNA extraction
20-30 ml of blood was drawn by venopuncture into EDTA tubes. DNA was
extracted according to a standard procedure (Blin and Stafford 1976).
2.2 Genotyping
In study I, gel electrophoresis in stage I of the genome scan was performed
on an ALF express automated DNA sequencer (Pharmacia Biotech) and
genotyping achieved by assigning allele numbers according to the
fluorescence curves generated. In stages II through IV gel electrophoresis
was done on an ABI 377 automated DNA sequencer (Applied Biosystems),
and genotypes were assigned using the Genotyper 2.0 software (Applied
Biosystems). Markers were from Weber screening set 6 (Sheffield et al.
1995). Markers that failed to work satisfactorily were replaced by markers
from the Généthon marker map. A total of 370 polymorphic microsatellite
markers on the autosomes and chromosome X (average spacing 10.5 cM)
were analyzed in stage I.
In studies II and III, PCR was performed according to standard procedures
and electrophoresis was done on an ABI 377 sequencer (Applied
Biosystems). Marker sequences were obtained from The Genome Database
<www.gdb.org>, and marker order and inter-marker distances were obtained
by RH mapping and by utilizing the Human Genome Project sequence data.
When sequence data were used, the genetic distance was estimated from the
physical distance assuming the equivalence of 1 million base pairs to 1 cM.
In study V, PCR was performed as described by Lichter et al. (1993) with
slight modifications. One primer was fluorescently labeled with Cy5 for size
separation on ALF express (Pharmacia Biotech). Genotyping was done using
the Allelinks (Pharmacia Biotech) software.
3 Statistical methods
In studies I-III, mendelian inheritance of alleles in the pedigrees was
confirmed by the PedCheck program (O'Connell and Weeks 1998). In all
statistical analyses we classified subjects as either affected or unknown. We
did not classify anyone as unaffected because unaffected family members
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were not systematically assessed. Therefore all the results are based on
’affected only’ analyses.
In both two-point and multipoint analyses, we wanted to minimize the problem
of type 1 errors due to multiple testing. To this end, we used oversimplified
inheritance models in all analyses. In two-point analyses one ’recessive’ and
one ’dominant’ model were analyzed, as detailed below. Correspondingly, in
multipoint analyses we considered only SimWalk’s statistics A and B, the two
most powerful statistics for detecting linkage to a recessive trait and a
dominant trait, respectively. Several liability classes were adapted for all
inheritance models and both the pedigree and nuclear family structures were
used in the analyses. The analyses of several different liability classes for one
inheritance model are not independent tests, but the obtained results still have
to be interpreted with due caution because of the multiple tests performed.
It has been demonstrated that the sib-pair mean test is statistically equivalent
to linkage analysis under a recessive mode of inheritance with no
phenocopies allowed, and an infinitesimally rare disease allele (Knapp et al.
1994). As implemented in the SIBPAIR program (Kuokkanen et al. 1996), this
has been shown to be one of the more reliable approaches to affected sib-pair
analysis, especially when extended to sibships with two or more affecteds
(Davis and Weeks 1997). This ’recessive’ model was therefore used in the
two-point analysis of the data. However, it is also possible to perform a
corresponding analysis assuming that the sib-pair shares alleles identical by
descent (IBD) from one of the parents, but not the other. Such a model has
been shown to be equivalent to linkage analysis with a dominant model, rare
disease allele, and no phenocopies (Kainulainen et al. 1999; Trembath et al.
1997). Therefore, such a ’dominant’ affected relative pair analysis was
performed using the MLINK program of the LINKAGE package, with technical
details described elsewhere (Kainulainen et al. 1999; Trembath et al. 1997).
For association analyses we used a generalization of the TDT test, the
gamete competition model (Sinsheimer et al. 2000), which can be employed
to test for biased transmission of marker alleles to affected individuals.
Because the null hypothesis is no association and no linkage, the method is
not purely a test of association as linkage in itself also affects the observed p-
value.
Due to of the great complexity of some of our pedigrees, most current
software packages for multipoint analysis cannot use the full pedigree
structure, but must rather simplify it in some way. One available program that
can utilize all of the information available from such complex pedigrees is
SimWalk2 (Sobel and Lange 1996), which uses a likelihood-based approach
for sampling from all possible configurations on general pedigrees. We
considered statistics ’A’ and ’B’ of SimWalk2.  The statistics measure the
degree of clustering among the affecteds of the founder-alleles, i.e. the
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marker alleles descending from the founders. Specifically, ’statistic A’ is based
on the number of different founder-alleles contributing  alleles to the affecteds,
while ’statistic B’ is based on the maximum number of alleles among the
affecteds descended from any one founder-allele. Since SimWalk2 uses all
available pedigree information, the calculation time for the complex pedigrees
in our study sample is of the order of months when analyzing all available
markers simultaneously (using a Compaq Alpha Server DS-10). We therefore
selected smaller subsets of the genotyped markers to be analyzed by this
method, based on the results of the two-point analyses. In all analyses, we
used the non-parametric analysis alternative of SimWalk2. The number of
replicates was 10,000 in all analyses.
In study IV, individual follow-up of patients, siblings and parents for cancer
started on January 1, 1971. For patients with a first diagnosis of schizophrenia
(or spectrum disorders) in the Hospital Discharge Register or Disability
Pension Register after this date, follow-up began from the date of first
diagnosis. For all three groups, individual follow-up ceased on December 31,
1996, or on the date of emigration or death if these occurred earlier. Person-
years were calculated by duration of follow-up (<2, 2-11, >11 completed years
of follow-up) and by 5-year age strata. Expected numbers of cancer cases
(total and specific cancers as classified by primary site) in each stratum were
obtained by multiplying the number of person years at risk by the
corresponding average incidence rate of cancer in the general population of
Finland during the same observation period. SIRs were calculated by dividing
the number of observed cancer cases in each group by the expected number
of cases. Calculation of 95% confidence intervals (CI) of SIR was based on
the assumption that the numbers of observed cases followed a Poisson
distribution.
For study V, we used the Pearson Chi-Square statistic for a table containing
the high and low scoring NS groups and the possible alleles of the studied
marker. The analysis was done using the SPSS 9.0.1 program (SPSS Inc.,
Chicago, Il)
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 ETHICAL CONSIDERATIONS
In addition to the general principles regulating biomedical research on human
subjects, a disorder like schizophrenia poses the scientist certain additional
ethical issues. Schizophrenia manifests itself in signs and symptoms that
encompass the entire range of human mental activity; it damages a variety of
functions that we regard as specifically human. The disorder is thus highly
stigmatizing to the subjects, and the importance of confidentiality cannot be
stressed enough. In our studies, we have followed the principles
recommended in the 1964 World Medical Association Declaration of Helsinki,
and its amendments. According to these principles, the subject can only be
contacted by the treating physician most familiar to the subject. The relatives
of the proband can only be contacted if and when the proband gives informed
consent.
The capacity of schizophrenic subjects to provide informed consent has been
discussed in the research community (Carpenter et al. 2000; Roberts 2000). A
current psychotic episode clearly makes informed consent difficult to obtain.
However, cognitive impairment can also make it difficult for some subjects to
understand the information provided prior to the request for consent. In
recognition of these concerns, we provided both written and oral information
to the subjects in our study. In general, the Helsinki declaration is appropriate
for protecting the rights of subjects, as the treating physician can always
refuse to contact the subject if the clinical condition so requires.
The decision to perform a study should take into account the ultimate goal of
the research and any possible abuse of the results, i.e. the ratio of possible
gain to the subjects and the possible harm which might be caused to the
subjects based on the obtained results. The potential gain from schizophrenia
research is naturally better understanding of the etiology of the disorder and
ultimately better treatment and/or prevention. However, a historical
perspective also makes it easy to imagine undesirable consequences of
genetic research on mental disorders, for example further stigmatization
based on biological markers, discrimination, and even eugenics. One cannot
be obtained without risk of the other, but in our opinion the potential benefits
of schizophrenia research outweigh these risks. Greater understanding of the
causes of schizophrenia would hopefully even reduce stigmatization and
discrimination.
The research was approved by the Ministry of Social Affairs and Health and
by the institutional review boards of the National Public Health Institute and
the University of Oulu (Study I).
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 RESULTS AND DISCUSSION
1 Genome-wide scan in sib-pair families from Finland
A schematic view of the general design of the study is given in Figure 8. To
optimize both cost-effectiveness and our chances of finding true positive
linkages, the study was performed in four stages, so that additional individuals
were genotyped or markers added at each stage based on the findings of the
previous stage.
In stage I, we genotyped 370 polymorphic microsatellite markers from the
Weber screening set 6 (Sheffield et al. 1995) in 52 affected sib-pairs (104
individuals) without parents. Thirteen markers resulted in lod scores over 0.5
and three markers produced Zmax>1.0. The highest pairwise lod scores were
found for markers D10S2325 (ASP Zmax=1.87), D5S1473 (ASP Zmax=1.46),
and D14S610 (ASP Zmax=1.49). On the basis of stage I data we selected
markers to be included in stage II.
Genome scan, two-point linkage
52 SP, only affected (N=104)
40 best markers
1o relatives of SP
15 best markers
134 SP with 1o relatives
Dense map for two best regions
Total study sample
Stage:
I
III
II
IV
Figure 8. Schematic overview of the four stages of study I.
(SP = Sib-pairs)
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In stage II we genotyped the 40 markers providing the highest lod scores in
stage I in DNA samples of parents or unaffected siblings of the affected sib-
pairs. This stage was expected to decrease the likelihood of false positives,
and to increase the ability to detect genotyping errors that might lead to false
negatives (Terwilliger et al. 1992), providing a more reliable basis for selection
of markers to be analyzed in the final stages.
In stage II, 23 markers resulted in affected sib-pair lod scores higher than 0.5,
ten of which were higher than 1.0. The markers providing the highest ASP lod
scores were D5S1473 (Zmax= 1.61) and D17S122 (Zmax= 1.60). For stage III
we selected the best 15 markers based on the data from stage II.
In stage III, we genotyped an additional set of affected sib-pairs and their first-
degree relatives, resulting in a total of 134 affected sib-pairs. Based on the
linkage analysis of the 15 markers included in this stage the two most
interesting regions were selected for further study in Stage IV.
In stage IV we genotyped 29 markers in the two chromosomal regions
providing the highest stage III ASP lod scores. These were a 16 cM region
around marker D7S1799 which resulted in the highest lod score in stage III
(ASP Zmax=2.42) and a 30 cM region around markers D1S1656 (ASP
Zmax=1.72 in stage III) and D1S2141, for which evidence of linkage was found
in a previous genome scan performed in the study sample from a sub-isolate
of Finland (Hovatta et al. 1999).
On chromosome 7, the region between markers D7S477 and D7S486
resulted in two-point lod scores up to 2.54 (D7S1799) under liability class 3. A
broad peak was observed between the same markers in multipoint analysis
using the MAPMAKER/SIBS 0.9 program (Kruglyak and Lander 1995). The
highest MLS, 2.62, occurred close to marker D7S1799.
We then incorporated the genealogical data collected for the families into the
statistical analyses. When only the families originating from the late settlement
region of Finland (Norio et al. 1973) were included in the analysis, the
obtained lod scores were higher. Marker D7S486 produced a two-point lod
score of 3.18 for the dominant model under liability class 3. Multipoint analysis
using MAPMAKER/SIBS resulted in a MLS of 3.53  between markers D7S501
and D7S523, under the broadest diagnostic model (class 4).
On chromosome 1 we identified a positive region between markers D1S439
and D1S1656, about 4.1 cM wide on the genetic map, which resulted in lod
scores up to 2.62 under the broadest diagnostic model and dominant mode of
inheritance. The same region was also implicated by multipoint analysis with
MAPMAKER/SIBS with a MLS of 2.51, between markers D1S439 and
D1S251.
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This study replicated the previous finding by Hovatta et al. (1999) performed
on a study sample from a genetically isolated region in northeastern Finland.
The markers providing the strongest evidence for linkage on chromosome 1 in
these two studies are about 15 cM apart on the genetic map, well within the
limits of expected variation of the lod score peak in study samples like these
(Roberts et al. 1999). The major problem with this study was that since only
affected siblings were identified in the first stage, false negative findings are
more likely, especially since not all genotype errors having a detrimental effect
on the allele sharing statistic could not be detected. The linkage to the
chromosome 7 region was novel and has not been replicated by other groups.
This finding is interesting, since one gene independently suggested as a
candidate gene for schizophrenia (RELN) is located in this region (Fatemi
2001), along with several other interesting candidate genes, e.g. Semaphorin-
3A (SEMA-3A). Interestingly, there is strong evidence for the involvement of a
gene on this chromosomal region in autism (IMGSAC 2001a, b). Even though
they are distinct diagnostic entities, autism and schizophrenia share some
common features, specifically the apparent social anhedonia can be thought
of as an overlapping symptom. In the future we will learn whether autism and
schizophrenia share any part of their genetic background on chromosome 7q.
The linkage in the chromosome 1 region has been replicated by several
groups and also contains one of the strongest candidate genes for
schizophrenia to date (DISC-1) (Millar et al. 2000). This region is discussed
more in detail in connection with study III.
2 Genome-wide scan in a population-wide sample from Finland
The sample collection continued during and after Study I. Experiences from
genome-wide scans for schizophrenia performed internationally had proven
that larger sample sizes were necessary in complex traits. We therefore
initiated the genome-wide scan of a study sample considerably larger than in
any of our previous studies. Moreover, the whole sample was included in all
stages of the study, in contrast to the previous studies that had been staged in
the interest of cost-effectiveness. This stage of the study was expected to
decrease false negative findings and to expose new chromosomal regions of
interest.
In two-point linkage analyses of the 53 pedigrees from the internal isolate, the
best evidence for linkage was obtained with marker D2S427 on chromosome
2q37. Using the recessive model of inheritance in nuclear families under the
most restricted diagnostic model, a two-point lod score of 4.43 was obtained
52
for this marker. Lod scores exceeding two were obtained for markers on
chromosomes 1 (D1S1728), 3 (D3S1311), 5 (GATA81C06) and 18
(D18S877).
In two-point linkage analysis of the families from the nationwide sample,
excluding the families from the internal isolate, the strongest evidence for
linkage , Zmax = 3.16, was obtained for marker D5S820 using liability class 1
and the dominant inheritance model. No other marker provided a lod score 
2.0 in the first stage of the analysis.
Like in Study I, the sample could be stratified based on the population history
of Finland into early and late settlement families. In total, 118 families
originating from the late settlement region of the country were analyzed with
the 27 markers giving lod scores  1 in the nationwide sample. Four markers
(D1S431, D4S2394, D5S1480 and D12S1294) provided increased evidence
for linkage compared to the nationwide sample, the most significant being
D5S1480 (Zmax = 2.05).
The total study sample consisted of 238 pedigrees and 1,251 genotyped
individuals. This study sample was analyzed for the best 62 markers from the
analysis of the individual samples. The best evidence of linkage (Zmax = 3.55)
was obtained for marker D5S820. Marker D2S427 yielded a lod score of 3.30
for liability  class 1.
Based on the two-point linkage analyses, two chromosomal regions appeared
the most interesting: chromosomes 2q and 5q. We conducted multipoint
analyses on these chromosomal regions using SimWalk2. We used only the
liability class and analyzed only the study sample that had shown the best
evidence for linkage in the two-point analyses in the corresponding region.
Isolate and All Finland:
LC 3-4
Combined: LC 1-4
Late settlement: LC1-4
Isolate and All Finland: LC 1+2
Fine mapping and multipoint analysis of
two best chromosomal regions
I
II
III
Figure 9. Schematic overview of the three stages of Study II (LC = liability
class). The whole study sample was used in all stages of the study.
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Due to its complicated structure and extensive size, the largest pedigree from
the internal isolate sample was always analyzed separately from the rest of
the pedigrees. On chromosome 2q, the best evidence for linkage was
obtained near marker D2S427 for the combined study sample with Statistic A
(–log10(p) =  2.5). On chromosome 5q the best evidence for linkage was
obtained near marker D5S480 for the late settlement study sample (–log10(p)
= 2.8). Based on these results, as well as previous linkage findings in this
region (Schwab et al. 1997; Straub et al. 1997), we pursued fine mapping with
30 markers over 14 cM on chromosome 5q. The
most significant result was obtained with the
families from the late settlement region (–
log10(p) = 3.7, Statistic A) near marker FGF1.
In conclusion, this study provided important
evidence for linkage for two regions not
identified in our earlier studies. The finding on
chromosome 2 is completely novel, with no
earlier reports of linkage to schizophrenia. The
chromosome 5 region, on the other hand, is
supported by several other studies (Figure 10),
especially noteworthy is one of the first
significant linkages found in schizophrenia
genetics (Sherrington et al. 1988). A recent
report on a genome-wide scan in Icelandic and
UK families showed evidence for linkage in the
same region (lod = 3.6, D5S422, (Gurling et al.
2001)), although this marker is some 20 cM
telomeric of the best marker in our study. A
study by Straub et al. also found support for a
region some 15-20 cM centromeric of D5S414 in
265 Irish pedigrees (D5S804, lod = 3.04, (Straub
et al. 1997)). One study of families from Israel
and Germany (Schwab et al. 1997), and another
of families from Palau (Byerley et al. 1999) have
provided further support for this region. The
findings from the present study have a high
statistical significance and have been produced
using one of the largest study samples collected
for genetic studies of schizophrenia to date.
Therefore both of them certainly warrant further
studies aimed at identifying the polymorphism
responsible for the increase in schizophrenia
susceptibility contained in the respective
regions.
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3 Detailed study of chromosome 1 in families with schizophrenia
Chromosome 1q has emerged as one of the major candidate regions for
schizophrenia based on several findings. The finding of Hovatta et al. (1999),
as well as data from Study I in this thesis made a relatively strong case for
linkage of schizophrenia in Finland to chromosome 1q31-42. One genome-
wide scan for bipolar disorder gave the second best evidence for linkage in
the same region (Detera-Wadleigh et al. 1999), as well as one genome-wide
scan for schizophrenia utilizing a study sample from Dagestan (Bulayeva et
al. 2000). One finding 60 cM more telomeric to this region also gained much
attention (Brzustowicz et al. 2000). The interest increased further when a
gene designated as disrupted in Schizophrenia 1 (DISC1) was identified
(Millar et al. 2000). A translocation disrupting this gene co-segregates with
schizophrenia in a large Scottish pedigree giving a lod score of more than 6.
This gene is located within 1-2 cM from the marker giving the strongest
evidence for linkage in Study I, making it a strong positional candidate gene
also for schizophrenia in the genetically isolated Finnish population. Based on
all of these findings, we set out to study chromosome 1q more in detail in
order to define the region of interest and to analyze the contribution of
different study samples to the linkage evidence.
The results of this study are presented separately for three different study
samples: 1) extended families with well established genealogical data from
the internal isolate of the late settlement region of Finland, 2) the generally
smaller families originating from the rest of Finland (referred to as ’nuclear
families’ hereafter), and 3) the two study samples combined.
For the combined sample, the highest lod score was obtained for marker
D1S2709 (lod = 2.71), adopting the dominant inheritance model and treating
individuals with schizophrenia spectrum disorders (liability class 3) as
affected. Several markers in a 2 cM region around this marker gave two-point
lod scores greater than 1.
For the families from the internal isolate of Finland marker D1S245 gave a lod
score of 2.30, again adopting the dominant model classifying all individuals
with schizophrenia spectrum disorders as affected (Figure 11). This region is
the same as the one identified in the previously published genome-wide scan
in this sub-isolate (Hovatta et al. 1999). Evidence for co-segregation was also
seen for marker D1S1728 (lod = 2.44, dominant model, liability class 3), which
is more than 100 cM proximal of D1S245.
For the nuclear families from the rest of Finland, marker D1S2709 gave the
strongest evidence for linkage (lod = 3.21), using a dominant model treating
individuals with spectrum diagnoses as affected (Figure 11). This marker is
within 3 cM of the peak identified in our previously published sib-pair genome-
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wide scan (Ekelund et al. 2000). No evidence for linkage to the position
identified in the internal isolate was found in these families.
The gamete competition model showed results significant at the 5% level for
17% of the markers, while this would have been expected of only 4% of the
markers by chance based on a gene-dropping simulation. The strongest
evidence for association and linkage for the combined study sample was seen
for marker D1S225 (p=0.009). The evidence for association and linkage to
this marker emerged exclusively from the nuclear families (p=0.005), while the
families from the internal isolate showed no evidence of association. This
marker is within 1 cM of marker D1S2709, which gave the strongest evidence
for linkage in this study.
One of the markers we genotyped (D1S484) is within 2 cM from the marker
that gave the strongest evidence for linkage to schizophrenia in a recent study
performed in Canadian families (Brzustowicz et al. 2000). This particular
marker provided only very weak evidence for linkage (lod=0.88) in our study.
For the 10 markers around D1S245 that showed evidence for linkage in the
two-point analysis of the families from the internal isolate, statistic B of
SimWalk2 gave the strongest evidence for linkage close to marker D1S245 (-
log10(p)=3.46) in families from the internal isolate. For this region the nuclear
families from the rest of Finland did not show evidence for linkage. The largest
pedigree from the internal isolate, with 31 affected family members, provided
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Figure 11. Two-point linkage results for familes from the internal isolate
and the rest of Finland, respectively.
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the majority of the statistical evidence for linkage, while the rest of the families
from this restricted geographical area contributed very little. For the 10
markers flanking marker D1S2709, which gave the strongest evidence for
linkage for the total study sample in the two-point analysis, statistic B of
SimWalk2 showed the strongest evidence for linkage close to marker
D1S2709 (-log10(p)=1.94). The evidence for linkage was obtained almost
exclusively from the nuclear families.
This part of the study did not provide any significantly stronger evidence for
linkage than the previous studies, nor were we able to restrict the area of
interest much from what was previously known. It is interesting, however, that
the results do not change much at all when such a massive amount of data is
added. Families from all over Finland were added, but the finding remained
roughly the same. This makes it likely that the possible susceptibility gene
contained in this chromosomal region has an effect on schizophrenia
susceptibility in families from all geographical areas of Finland. We cannot
with certainty tell whether the two linkage peaks observed in the two sub-
samples truly reflect two separate susceptibility loci or whether they merely
reflect stochastic variation in the localization of the lod score peak in different
samples. As can be seen from Figure 12, a substantial amount of evidence for
linkage to chromosome 1q has been published recently. All findings taken
together, it is likely that chromosome 1q contains at least one  gene that has a
detectable effect on schizophrenia susceptibility. Several groups are presently
investigating this region to identify and characterize the putative psychosis
gene.
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Figure 12. Overview of linkage findings on chromosome 1 in studies of
schizophrenia and bipolar disorder. From the left, the bars represent the
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4 The incidence of cancer in patients with schizophrenia and their
first-degree relatives
The multicenter WHO collaborative study of cancer incidence in schizophrenic
study samples showed that the incidence of lung cancer in particular was
decreased, but left the reasons behind this counterintuitive finding unexplored
(Gulbinat et al. 1992). To take this matter one step further we used the
extensive and relatively complete registers available in Finland to verify this
finding and also to study the incidence in the first-degree relatives of the
schizophrenic patients to explore familial-environmental hypotheses about this
paradox.
After exclusion of 698 individuals who had died before the starting date of the
follow-up, 26,996 patients with schizophrenia, 52,976 of their non-
schizophrenic siblings, and 39,131 of their parents were eligible for follow-up.
This corresponded to 446,653, 1,438,143 and 905,947 accumulated person
years at risk of cancer (or a mean of 16.5, 27.1, and 23.2 years at risk per
subject) respectively. Of all the cases reported to the Finnish Cancer Registry,
1,533 were benign lesions (mainly basal cell carcinomas of the skin) and thus
excluded.
Among patients with schizophrenia, 724 cancers were diagnosed during
follow-up while 619 would have been expected from the incidence in the
general population. The overall risk of cancer was significantly increased (SIR
1.17; 95% CI, 1.09-1.25), more so in males than females. The largest
increases were found for primary cancer of the lung (SIR 2.17; 95% CI, 1.78-
2.60) and pharynx (SIR 2.60; 95% CI, 1.25-4.77). A significant increase was
also seen for cancer of the gall bladder (SIR 2.07; 95% CI, 1.03-3.70), the SIR
being higher in males (SIR 3.01; 95% CI, 0.98-7.01) than in females (SIR
1.64; 95% CI, 0.60-3.57). The SIR for rectum (SIR 0.35; 95% CI, 0.13-0.75)
cancer was decreased and that for cancer of the corpus uteri increased (SIR
1.75; 95% CI, 1.19-2.48).
Among non-schizophrenic siblings and parents of schizophrenia patients
fewer cases of cancer emerged than expected (siblings: 886 vs. 999; SIR
0.89; 95% CI, 0.83-0.94; parents: 6,165 vs. 6,755; SIR 0.91; 95% CI, 0.89-
0.93), similarly in both sexes. Decreased incidences of lung cancer (SIR 0.82;
95% CI, 0.68-0.97) and breast cancer (SIR 0.77; 95% CI, 0.71-0.83) were
seen in patients’ mothers but not in other relatives. Cancer of the corpus uteri
occurred less frequently than expected both in mothers (SIR 0.81; 95% CI,
0.69-0.92) and sisters (SIR 0.38; 95% CI, 0.14-0.83). Prostate cancer in
patients’ fathers also occurred at a lower rate, though the 95% CI included
unity (SIR 0.57; 95% CI,  0.26-1.08). The incidence of colon cancer in parents
was lower than expected (291 vs. 347; SIR 0.84; 95% CI, 0.75-0.93).
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Based on these results we can conclude that cancer incidence is really
increased among Finnish individuals with schizophrenia and decreased
among their first-degree relatives compared to the general population. The
finding of increased incidence among the schizophrenic subjects is consistent
with what is known about the smoking prevalence and intensity in this group
of patients. As a matter of fact, the relative increase in cancer incidence is not
statistically different from what would be expected based on the smoking data
available, even though data on smoking was not available on the individual
level (Jablensky and Lawrence 2001). The finding in the relatives is not as
readily understandable. Some factor obviously decreases one’s risk of being
diagnosed with cancer if one has a first-degree relative diagnosed with
schizophrenia. It is unclear what this factor could be, but both environmental
and genetic factors are conceivable. One possible environmental factor is
relatives becoming more health-conscious when their sibling or child develops
schizophrenia and consequently being less exposed to carcinogenic agents.
This seems unlikely to explain a large deviation in cancer risk among
relatives, but cannot be ruled out. A completely hypothetical genetic risk factor
could decrease the risk of malignancy while increasing the risk of developing
schizophrenia. The protective effect of such a gene would be seen among
first-degree relatives of schizophrenic patients since they share on average
half their genome with the patients, but could be overridden in the patients by
their excessive use of tobacco and alcohol, among other risk factors.
5 The association between novelty seeking and DRD4
The exponential rise in risk of schizophrenia with increasing degree of genetic
relationship indicates the importance of non-linear interactions among multiple
genetic factors (Risch 1990b). If it holds true that some complex disorders,
like schizophrenia, are caused by interactions among several susceptibility
dimensions, each of which may be oligogenic, replication of particular genes
is unlikely using the sample sizes that are possible to collect (Risch 1990a).
The idea behind this study was to identify genes contributing to temperament,
which has a relatively simple genetic architecture. If such genes are identified,
susceptibility to e.g. schizophrenia could be evaluated in terms of risk from
heritable temperament measures and disease-specific factors. The total allele
frequencies in our sample were similar to the allele frequencies in a Finnish
control population published earlier (Malhotra et al. 1996). The distribution of
the NS scores is shown in Figure 13. The mean score was 20.3 (95%
confidence interval for the mean 20.2-20.5, SD = 5.9). All the subjects
included in the analysis had NS scores more than 1 SD from the mean of
the cohort (NS score in low scorers ≤ 12, in high scorers ≥ 31) and the means
for the extreme groups (7.48 and 33.48 respectively) lay outside 1.96 SD
from the mean for the whole group.
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Contrary to the original finding (Benjamin et al. 1996; Ebstein et al. 1996) the
7 allele was less common among our high scorers, whereas the 2 and 5
repeat alleles were more frequent in this group. One subject had an 8-repeat
allele, and this was pooled with the 7-repeat allele group in all analyses. For
10 individuals DNA did not amplify satisfactorily and they were excluded in all
analyses.
The value for the Pearson Chi-Square statistic was 14.1, which for 4 degrees
of freedom corresponds to a global p-value of 0.007 for both sexes together
over the contingency table. The sex-specific analysis using the chi-square
statistic was hindered by too small expected values for some of the cells.
However, a trend in the same direction as for the sample as a whole was
observed. When allele 5 was pooled with the allele closest to it in size (allele
4) there was a non-significant trend in the same direction as for the whole
sample (males: χ2 = 4.1, 3 df, p = 0.248; females: χ2 = 5.8, 3 df, p = 0.123).
As can be seen from the above, the association we observed was in the
opposite direction compared to the original findings, that is the 7-repeat allele
was less common among high NS scorers in our sample than among low
scorers, and the opposite holds true for the shorter alleles (2- and 5-repeat
alleles). There are several explanations for this discrepancy. First of all, both
findings might naturally be false positive, a possibility that can only be ruled
out by further, independent studies of this issue. Secondly, our study sample
might in some important way differ from the original reports (Benjamin et al.
1996; Ebstein et al. 1996). For example, since we included only extreme NS
scorers we might actually have included a larger proportion of subjects with
any diagnosable personality disorder or other mental disorder. One might
speculate therefore that the finding in our study is primarily related to any
such disorder and only secondarily to Novelty Seeking (Malhotra and
Goldman 2000). Thirdly, it has been postulated that there could be a non-
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linear relationship between a quantitative trait and frequency of a certain
variant of a gene that truly has an effect on that trait. This has been shown to
be the case for example between neuroticism and a polymorphism in the
promoter of the serotonin gene (Sirota et al. 1999). If this is also the case for
NS and DRD4, our results are difficult to interpret due to our sampling
strategy. The last and probably most plausible explanation is that the studied
polymorphism is actually not the one influencing NS scores, but that it is
merely in linkage disequilibrium with the true, causative variant. Another
variant, namely a -521 C/T polymorphism in the promoter region of DRD4,
has also been found to be associated with NS scores (Okuyama et al. 2000).
In our sample however, this specific polymorphism was not associated with
NS scores (Ekelund et al. 2001). It is therefore possible that yet another
polymorphism in the DRD4 gene, its regulatory region or in a gene closely
situated on the chromosome is actually the one influencing NS scores. Taken
together, these results replicate the original findings of an association
between NS and DRD4. If this association holds true, it is the first finding of a
gene that has an effect on variation in a normal behavioral trait. Identification
of genes for normal personality may shed some light on the etiology of
psychopathology as well.
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 CONCLUDING REMARKS AND FUTURE PROSPECTS
This study began in the spring of 1996, since when much has happened in the
field of genetics, and specifically in the field of psychiatric genetics. Dense
marker maps and high-throughput genotyping techniques have replaced the
earlier sparse maps and labor-intensive genotyping methods. In 2001,
moreover, the first draft of the sequence of the human genome was
published, a major milestone in biological and medical research.
Some less welcome insights in psychiatric genetics have emerged during this
time. While many involved scientists in 1996 believed that a major gene for
schizophrenia, or any other major mental illness, would soon be identified, we
have now learned that such major genes probably do not exist and that most
common psychiatric disorders are genetically complex and heterogeneous.
This has influenced the way scientists conduct genetic studies. Less than ten
years ago many studies were published that reported linkage in one or only a
few pedigrees. Studies of this type have now been replaced by massive
efforts by international research institutions, both academic and commercial,
to pool study samples from multiple populations. The future will hopefully and
probably see even bigger collaborations aimed at achieving sample sizes
sufficiently large also to detect genes of minor effect.
1996 saw the first publication describing a genetic variant affecting normal
human behavior. This finding, if it holds true, will certainly have an effect on
how we view ourselves as human beings. Spurred by this original finding
much research is now being conducted on normal variation in behavior. In the
future, findings of this kind will tell us a lot about how the human brain works
and also what goes astray when some parts of the brain function abnormally,
resulting in psychiatric disorders.
The present study has made contributions to three areas of research: 1) The
search for susceptibility genes for schizophrenia, 2) The genetics of normal
human behavior, 3) The comorbidity of schizophrenia. While these
contributions have naturally been small, they have still expanded our
knowledge of the genetics of psychiatric diseases in Finland.
During the past few years the importance of the diagnostic process in genetic
studies on mental disorders has, if anything, increased. Not only is it
necessary to use diagnostic systems with high reliability, but developing new
diagnostic categories might also be a vital prerequisite to identify susceptibility
genes for any psychiatric disorder. It is possible that the present practice of
using clinically based diagnostic systems might not prove valid enough from a
pathophysiological perspective. These systems have high reliability, a feature
necessary for clinical use, but might not define pathophysiologically distinct
entities. It might be necessary to measure more fundamental quantitative
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traits that have a closer relationship to the underlying pathophysiology.
Therefore development of radiological, neurophysiological and
neuropsychological measures that reliably and significantly define some sub-
population of schizophrenic patients might be necessary before we can get a
firm grasp on the genetic background of schizophrenia.
Much work will be required in the fields of bioinformatics and statistics. We
need biocomputing tools capable of handling much larger amounts of data
than are presently available, and also statistical tools able to manage
completely new kinds of data. We will need to be able to determine genome-
wide genetic profiles, to identify gene families and to predict function from
structure. New techniques monitoring expression profiles and interaction
between genes will require new biocomputing tools. In addition, we will need
statistical methods to analyze larger amounts of data - both genotype and
genealogical - and to control for numerous quantitative, epistatic and other
complex effects of human genes.
The new findings in genetics, especially complex genetics, have also had
some effect on the opinions and views of the public, and hopefully this
influence will increase. The common view of "genetic" disorders has largely
been influenced by the early findings of causal connections between
mutations and disorders in the rare, monogenic disorders. We now know that
most common disorders are genetically complex, with both genetic and
environmental factors having an effect on the onset and outcome of the
disorder. Therefore most disorders are not "genetic" or "environmental"; they
are both. Hopefully, this insight will start to shift common views of genetics
away from fatalistic determinism and towards a heuristic optimism that much
is still to be learned about the etiology, pathophysiology and potential
interventions of common disorders, and specifically mental disorders, based
on their genetic background.
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